No Prescription |
 |
 | ||
|
Acyclovir Generic Zovirax |
|
| ||
No Prescription » Prescription Drugs 1 » Acyclovir Generic Zovirax This medication is used to treat "cold sores/fever blisters" (herpes labialis). It can speed up healing of the sores and decrease symptoms (such as tingling pain burning itching). Acyclovir belongs to a class of medications known as antivirals. It works by stopping the growth of the virus. This medication does not cure herpes and it does not prevent passing the infection to someone else. It does not prevent a future occurrence. Buy Acyclovir Generic Zovirax and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Acyclovir Generic Zovirax: Product Type: Prescription Drugs 1 Acyclovir (Generic Zovirax Aciclovir) Product Origin: United Kingdom Acyclovir (Generic Zovirax Aciclovir) Generic Zovirax Aciclovir 5% 60gm(6 x 10gm) 6gm(3 x 2gm) 30gm(3 x 10gm) Generic Zovirax Aciclovir Acyclovir
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
